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ABSTRACT
Malignant pleural mesothelioma (MPM) is a cancer of the pleural cavity resistant 
to chemotherapy. The identification of novel therapeutic targets is needed to improve 
its poor prognosis. Following a review of literature and a screening of specimens we 
found that platelet-derived growth factor receptor beta (PDGFRB) is over-expressed, 
but not somatically mutated, in MPM tissues. We aimed to ascertain whether PDGFRB 
is a MPM-cancer driver gene. The approaches employed included the use of gene 
silencing and the administration of small molecules, such as crenolanib and imatinib 
(PDGFR inhibitors) on MPM cell lines (IstMes2, Mero-14, Mero-25). Met5A cells were 
used as non-malignant mesothelial cell line. PDGFRB-silencing caused a decrease in 
the proliferation rate, and a reduced colony formation capacity, as well as an increase 
of the share of cells in sub-G1 and in G2 phase, and increased apoptotic rate of MPM cell 
lines. Loss of migration ability was also observed. Similar, or even further enhanced, 
results were obtained with crenolanib. Imatinib showed the least effective activity 
on the phenotype. In conclusion, our study highlights PDGFRB as target with a clear 
role in MPM tumorigenesis and provided a rationale to explore further the efficacy of 
crenolanib in MPM patients, with promising results. 
INTRODUCTION
Malignant pleural mesothelioma (MPM) is a 
cancer of the pleural cavity with a poor prognosis and 
the identification of novel therapeutic targets is urgently 
needed. Recently, our research group investigated the 
expression status of 119 candidate cancer genes in MPM 
tissues and cell lines. Among the identified genes, one 
of the most interesting was PDGFRB encoding for the 
platelet-derived growth factor receptor beta, already 
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suggested as a MPM-cancer gene by previous research 
groups [1,2]. PDGF is composed of homo-dimers or 
hetero-dimers of two polypeptide chains, denoted A and 
B. Two different PDGF receptors, alpha and beta, have 
been described [3,4]. The two receptor subtypes show 
different affinities for the dimeric PDGF isoforms. The 
PDGF-alpha receptor binds with high affinity all three 
forms (i.e. AA, AB, and BB), whereas the beta-receptor 
subtype only binds PDGF-BB [5,6]. It is a confirmed 
observation that panels of MPM cell lines express 
preferentially PDGF beta-chain and PDGF beta-receptor 
transcripts, whereas normal mesothelial cell lines do not 
express PDGF B-chain mRNA and little or no PDGF beta-
receptor mRNA [7]. In contrast, normal mesothelial cell 
lines were found to express PDGF alpha-receptor mRNA, 
which could not be detected in mesothelioma cell lines 
[7]. It has been suggested that the PDGF/PDGFR-beta 
interaction could be involved in the carcinogenesis of 
various tissues, including osteosarcoma [8], meningiomas, 
melanomas, neuroendocrine tumors, ovarian, pancreatic, 
gastric, lung, prostate cancers [9], and MPM [10], with 
both autocrine and paracrine mechanisms of growth 
stimulation. In agreement with this, it has been shown that 
PDGFRB is also associated with the aggressive behavior 
of several types of tumors. The 60% of colon cancer 
patients express high levels of this gene and the PDGFRB 
expression correlates with lymphatic dissemination of this 
cancer [11]. Steller EJ showed that PDGFRB signaling in 
mesenchymal-like tumor cells (as colorectal cancer cells) 
contributes to invasion and liver metastasis formation [12]. 
High PDGFRs expression correlates with advanced stage 
disease and poor prognosis in breast [13], liver [14], and 
pancreatic carcinomas [15].
Given the role of PDGFRB in cancer, a plethora 
of PDGF/PDGFR pathway inhibitors are available and 
assayed in clinical trials for leukemia, gastrointestinal 
stromal tumors (GIST), and glioma (https://clinicaltrials.
gov/). Thus, it is of interest to explore whether MPM 
patients may also benefit from the use of these agents. 
To this end, in the present work we studied the effect of 
PDGFRB inhibition in MPM cell lines. The approaches 
included the use of gene silencing and PDGFRB 
inhibitors. The results support PDGFRB up-regulation as 
a cancer-driver mechanism and suggest this receptor as a 
candidate therapeutic target worth to be exploited in the 
treatment of this disease.
RESULTS
PDGFRB somatic mutation screening
Given that previous works and our investigations 
highlighted that between 20-40% of MPM specimens 
over-express PDGFRB [2,16,17], we wondered whether 
MPM tissue samples may bear somatic mutations within 
the PDGFRB locus. Thus, the tyrosine kinase loop 
domain encoded by exons 12-18 was screened on a 
series of 96 MPM specimens. We found only a common 
polymorphism, but no somatic mutations (Table S1). Next, 
to further study the possible mechanism of PDGFRB 
over-expression in MPM, we analyzed the copy number 
alterations of the PDGFRB genomic region in 83 MPM 
patients whose data were deposited in The Genome Cancer 
Atlas database (TGCA, URL at http://cancergenome.nih.
gov/cancersselected/Mesothelioma). Even in this case, any 
significant amplification was detected in correspondence 
of PDGFRB genomic region (data not shown for brevity).
PDGFRB expression in MPM cell lines
The expression level of PDGFRB was screened on a 
panel of three human MPM cell lines: Mero-14, Mero-25, 
and IstMes2. The SV40-immortalized Met5A cell line was 
used as a model of non-malignant mesothelial cells. As 
shown in Figure 1A, all MPM cells showed up-regulated 
PDGFRB expression. Mero-14 cells showed the highest 
amount of mRNA expression level of around 70-fold 
compared to that of the Met5A cell line. Mero-25 cells 
showed an increased expression of about 30-fold, whereas 
IstMes2 cells had a 10-fold increase. All these differences 
were statistically significant using Met5A as reference 
(P=6x10-3, P=0.01, and P=3x10-3, respectively). Protein 
expression analysis gave similar results. The highest levels 
of PDGFRB protein was found in Mero-14 cells with an 
average increase of 99% when compared to Met5A cells. 
Mero-25 cells showed an increase of 97%, whereas the 
IstMes2 cell line had an increase of 70%, as shown in 
Figure 1B. To study further the role of PDGFRB gene, all 
four cell lines underwent RNA interference (RNAi). The 
silencing efficiency was measured at mRNA and protein 
levels. Mero-14 and IstMes2 cells showed a reduction of 
PDGFRB expression of about 95% whereas the Mero-
25 cell line showed a silencing efficacy of about 50%. 
Met5A cells showed at least 70% PDGFRB depletion at 
the protein level, although the quantification was difficult 
given the minimal PDGFRB expression before RNAi. 
The results are shown both at mRNA and protein levels in 
Figure 1C and D, respectively.
PDGFRB silencing and cellular growth
SRB assay was performed to evaluate the effect 
of PDGFRB silencing on cellular growth of MPM cell 
lines. Following the administration of siPDGFRB, the 
proliferation rate was significantly reduced for Mero-
14 (P=2x10-3) and IstMeS2 (P=6.7x10-3) cells, when 
compared to cells treated with C- PDGFRB. This 
reduction was particularly evident from the third day of 
treatment, and further decreased on day 8 by 30% and 
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34% respectively (Figure 2A). Mero-25 did not show 
any reduction, whereas the depletion of PDGFRB did 
not produce any effect on Met5A cells. In parallel with 
the measurement of the proliferative capabilities of 
cells, a colony formation assay was used to evaluate the 
clonogenic capacities of silenced cells. As shown in Figure 
2B, PDGFRB silencing had a strong effect on abolishing 
clonogenicity in Mero-14 (-80.1%; P=2.9x10-3) and 
IstMes2 (-86.3%, P=5x10-4), when compared to control 
C- PDGFRB-transfected cells. A slight reduction of 
colony formation capacity was also observed in Mero-25 
cells after PDGFRB silencing, but this decrease was not 
statistically significant (data not shown). No effect was 
detected on the non-MPM cells Met5A.
PDGFRB silencing and cell cycle progression
The effect of PDGFRB-silencing on the progression 
of cell cycle was evaluated through flow cytometry 
analysis. In IstMes2 cell line, siPDGFRB induced an 
Figure 1: Expression levels of PDGFRB in Mero-14, IstMes2, and Mero-25 human MPM cell lines and Met5A. A. 
RT-qPCR showing the mRNA expression levels of PDGFRB measured on MPM cell lines and related to Met5A cells (set to 1). RPLP0, 
HPRT, and TBP were used for normalization. Error bars show the standard error of the mean (SEM) from three independent experiments, 
each performed in triplicate. B. Protein levels of PDGFRB in Mero-14, IstMes2, Mero-25, and Met5A cells. β-actin was used as reference. 
The protein levels were confirmed by two independent experiments. C. RT-qPCR showing the mRNA expression levels of PDGFRB in 
Mero-14, IstMes2, Mero-25, and Met5A cells, after siPDGFRB administration, related to their own C-PDGFRB (set to 1, dotted black 
bar). RPLP0, HPRT, and TBP were used for normalization. Errors bars are SEM, from three independent experiments, each performed in 
triplicate. D. Protein levels of PDGFRB after its depletion in Mero-14, IstMes2, Mero-25, and Met5A cells. β-actin was used as reference. 
The protein levels were confirmed by two independent experiments. 
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increase of the share of cells in sub-G1 (P=0.03), a decrease 
of cells in G0/G1 phase (P=1.4x10-3), and an increase of 
the share of cells in G2/M checkpoint phase (P=10-3), as 
compared to the same cells treated with C-PDGFRB. A 
similar trend, not statistically significant, was also shown 
for Mero-14 cells. No effects were detected on Met5A and 
Mero-25 cells (Table S2, A). 
PDGFRB silencing and apoptosis 
The activity of caspases 3 and 7 was measured for 
the evaluation of the apoptotic rate following PDGFRB 
silencing. After the transfection with siPDGFRB, Mero-
14 and IstMes2 cell lines showed an average increase 
of caspase activity of 62% and 34%, respectively 
(C- PDGFRB used as control P<10-3 and P=9x10-3, 
respectively). The increase of apoptotic cells in IstMes2 
was of the same order of magnitude as the increase of 
sub-G1 cells measured with flow cytometry. No changes 
were observed in Mero-25 and MeT5A cells (Figure 3A).
PDGFRB silencing and migration capacity
Wound-healing assay was employed to assess the 
effect of PDGFRB silencing on cellular migration of 
MPM cell lines. No statistically significant differences 
in migration were observed in Mero-25, IstMeS2, and 
Met5A cells following the siPDGFRB administration. 
Nevertheless, Mero-14 cells showed a statistically 
significant reduced migration ability, as compared to 
Figure 2: Role of PDGFRB in cellular growth. A. SRB proliferation assay in Mero-14, IstMes2 and Met5A cells treated with 
50 nM of the C-PDGFRB or siPDGFRB. Error bars represent SEM of three independent experiments, each performed in quadruplicate. 
B. Clonogenic assay: representative micrographs of colonies formed by C-PDGRB (top) and siPDGFRB (bottom) transfected Mero-14, 
IstMes2 and Met5A cell lines on the left and the corresponding histograms of each measurement on the right. Two different experiments 
were performed, each in triplicate.
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C-PDGFRB, at 72 h after PDGFRB depletion (P=0,019) 
(Figure 3B).
PDGFRB silencing and anchorage-independent 
growth capacity
Soft agar colony formation assay was performed 
to evaluate the malignant transformation potency on 
anchorage-independent growth of MPM cells with 
or without the administration of siPDGFRB. Colony 
formation on soft agar was observed in C-PDGFRB cells 
(Figure 4), whereas siPDGFRB treatment significantly 
decreased both size and number of soft agar colonies 
formed by Mero-14 and IstMes2 cells (P=0.006 and 
P=0.007 respectively). Mero-25 cells were not able to 
form colonies on soft agar in both treated and control 
conditions, even after 28 days of culture (data not shown). 
No significant differences were detected in Met5A cell 
line. Hence the results of the soft agar assay confirmed 
that PDGFRB depletion decreased in vitro tumorigenic 
potential of MPM cells.
PDGFRB drug inhibitors and cellular growth 
We next tested two PDGFRB inhibitors: crenolanib 
and imatinib. These small molecules are known to act by 
preventing PDGF-induced PDGFR autophosphorylation, 
and their effect on MPM cell lines was then compared. 
Similar to that found after PDGFRB gene-silencing, 
reductions of proliferative capabilities were observed, 
where the strongest activity of crenolanib was found 
on Mero-14 and IstMes2 cells, as reported in Figure 
5A. The proliferation rate of Mero-14 cells suffered a 
reduction of about 25% (statistically significant, P=0.03), 
whereas IstMes2 cells reached a 40% reduction (P=0.04). 
Mero-25 cells seemed poorly sensitive to crenolanib, 
as the growth rate was only reduced slightly. No effect 
was found on Met5A cells. In this respect, the response 
of all cell lines was overlapping to that observed after 
siPDGFRB administration. Similar results were obtained 
Figure 3: A. Role of PDGFRB in apoptosis. Caspase activity measured on Mero-14, IstMes2, and Met5A cells transfected with 50 nM 
of C-PDGFRB (set to 1, black bar), or siPDGFRB. A marked increase in apoptosis is observed for Mero-14, IstMes2 cells, but not for the 
non-MPM Met5A cells. Error bars represent SEM of three independent experiments, each performed in triplicate. B. Role of PDGFRB on 
cellular migration. Confluent monolayers of Mero-14 (left) and Met5A (right) cells transfected with 50 nM of C-PDGFRB, or siPDFRB, 
respectively. Two different experiments were carried out, each performed in triplicate. Massive effect was observed in the wound-healing 
assay, following siRNA transfections, for Mero-14 cells. Met5A did not respond to siPDGFRB in the migration ability.
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after treatment with imatinib (Figure 5B), but with 25-fold 
higher doses. When an arbitrarily chosen and intermediate 
concentration of 8 µM for both molecules was employed, 
as expected, the inhibitory effect of crenolanib was much 
stronger, whereas imatinib was almost ineffective (P = 10-
4, data not shown).
Crenolanib (at 1µM) and imatinib (at 25µM) were 
both efficient in abolishing the colony formation capacity 
of Mero-14 (Pcrenolanib = 2x10-3; Pimatinib = 6.3x10-10), IstMes2 
(Pcrenolanib = 2.3x10-3; Pimatinib =1.48x10-8), and Mero-25 cells 
(Pcrenolanib=0.02; Pimatinib=2x10-4), without any statistically 
significant effect on the clonogenic survival of the Met5A 
cell line (Figure 6).
PDGFRB drug inhibitors and cell cycle 
progression
Similar to the observations made following 
treatment with siPDGFRB, the flow cytometry analysis 
showed that crenolanib induces an increase in the share 
of cells in sub-G1 for Mero-14 (P=2x10-3) and IstMes2 
(P=0.04), a reduced share of cells in G0/G1 phase (P=1x10-
3 for Mero-14 cells, and P=0.05 for IstMes2 cells), and an 
accumulation in G2/M phase for IstMes2 cells (P=0.04). 
In addition, an accumulation in G2/M phase was also 
observed for Mero-25 cells (P=0.01). The treatment with 
imatinib affected the cell cycle progression with lower 
efficacy compared to crenolanib: a statistically significant 
accumulation (P=0.02) of cells in G2/M phase was found 
only for IstMes2 cell line. Met5A did not experience 
significant changes in the cell cycle progression during 
the treatment with either of these drugs (Table S2, B-C).
PDGFRB drug inhibitors and apoptosis 
The caspase 3 and 7 activities were assayed on 
the four cell lines, after 72 h of a crenolanib or imatinib 
continuous treatment. With crenolanib at 1µM (Figure 7A), 
Mero-14 and IstMes2 showed a strong and statistically 
significant increase of apoptosis (+54%, P=3.8x10-3, 
and +100% P=0.017, respectively), in agreement with 
the share of sub-G1 cells observed with flow cytometry 
analysis. Mero-25 showed an increased apoptosis rate 
(+34%), but this was not statistically significant (P=0.12). 
Met5A cells had increased apoptosis (+20%), slightly 
statistically significant, and not confirmed with the share 
Figure 4: Role of PDGFRB in anchorage-independent growth capacity following siPDGFRB transfection. Representative 
images of soft agar colonies formed by C-PDGRB and siPDGFRB transfected Mero-14, IstMes2 and Met5A cell lines (top) and the 
corresponding histograms of each measurement (bottom). Error bars represent SEM of two independent experiments, each performed in 
triplicate.
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of sub-G1 cells observed with flow cytometry analysis. 
Imatinib treatment was not associated with increased 
apoptosis in any treated cell line. 
PDGFRB drug inhibitors and migration
The cell migration ability of MPM cells was 
heavily compromised by treatment with crenolanib. 
Mero-14, IstMes2, and also Mero-25 treated cells showed 
a statistically significant difference in the closure of the 
scratch compared to the corresponding controls (Figure 
7B; P=0.04; 0.02; 7x10-3 respectively). Imatinib treatment 
affected the migration capacity of Mero-25 cells with 
statistical significance (P=4x10-3), but not that of Mero-
14 and IstMes2 cells (Figure 7C), compared with their 
corresponding controls. Met5A cells were not able to 
close the scratch completely, and the difference with their 
corresponding control was not statistically significant.
PDGFRB drug inhibitors and anchorage-
independent growth capacity
Crenolanib and imatinib treatment significantly 
decreased both size and number of soft agar colonies 
formed by Mero-14 (Pcrenolanib = 6x10-5; Pimatinib = 4x10-7) 
and IstMes2 cells (Pcrenolanib = 0.02; Pimatinib = 0.007) similar 
Figure 5: Role of PDGFRB in cellular growth, following treatment with chemotherapeutic drugs. A. Proliferation assay 
in Mero-14, IstMes2, Mero-25, and Met5A cells treated with DMSO or 1µM of crenolanib. Error bars represent SEM of three independent 
experiments, each performed in quadruplicate. B. Proliferation assay in Mero-14, IstMes2, Mero-25, and Met5A cells treated with DMSO 
or 25µM of imatinib. Error bars represent SEM of three independent experiments, each performed in quadruplicate.
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to that observed for siPDGFRB treatments. Mero-25 cells 
did not form colonies in any of the treatment conditions, 
nor in control (data not shown). Met5A did not show 
differences in soft agar colony formation capacity when 
treated with crenolanib compared to DMSO. These cells 
were more affected by imatinib treatment, forming smaller 
colonies than those of the control. However, the difference 
is not statistically significant (Figure 8).
DISCUSSION
In this work we studied somatic mutations within 
PDGFRB and the inhibition of PDGFRB on MPM. No 
activating gene mutations were detected and these results 
are in agreement with that found both in COSMIC (http://
cancer.sanger.ac.uk/cosmic) and TGCA databases. The 
former reports that, unlike PDGFRA, PDGFRB gene is 
not frequently mutated at somatic level in cancer tissues 
(only 276 simple mutations in a total of 26.218 tested 
samples), the latter shows one missense mutation among 
83 MPM specimens (1.2%). On the other hand, MPM 
cells over-express PDGFRB mRNA [17] and 20-40% of 
MPM specimens show immuno-reactivity for PDGFR 
beta-chain. Normal mesothelium usually does not show 
PDGFRB mRNA and protein expression [18]. Thus, 
it should be hypothesized that the tumor progression in 
MPM is driven by PDGFRB over-expression rather 
than its activating mutations. This suggests a completely 
different mechanism to that observed in GIST, where 
somatic mutations are frequently found within PDGFRA. 
Figure 6: Role of PDGFRB in cellular growth, following treatment with crenolanib, and imatinib. A. Clonogenic 
assay: representative micrographs of colonies formed by Mero-14, IstMes2, Mero-25, and Met5A cell lines treated with DMSO (top) 
and crenolanib (1µM, bottom). B. Clonogenic assay: representative micrographs of colonies formed by Mero-14, IstMes2, Mero-25, and 
Met5A cell lines treated with DMSO (top) and imatinib (25µM, bottom). C. Histograms corresponding to each measurement performed for 
crenolanib and imatinib. Two different experiments were performed, each in triplicate.
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A generalized overexpression of PDGFRB could be 
explained by a gain of the copy number of this gene. 
Preliminary observations at low resolution using 
fluorescence in situ hybridization suggested that less than 
10% of MPM patients could show this phenomenon [19]. 
However, a search in TGCA portal showed that none of the 
83 specimens had significant chromosomal gain/losses of 
the locus. Overall, these results suggest that the increased 
expression of PDGFRB should be ascribed to changes at 
transcriptional level and not to gene amplification. 
It was also suggested that the cell growth 
stimulation triggered by PDGFRB could be caused by an 
autocrine loop, leading to the activation of tyrosine kinase 
receptors in MPM cells. The finding that ligands activating 
PDGFR populate the tumor stromal microenvironment 
seems to corroborate this hypothesis [20]. Thus, overall, 
these data suggest that PDGFRB is an important receptor 
involved in MPM progression. However, more research 
is warranted in order to provide further evidences. Thus, 
we analyzed the impact of PDGFRB gene silencing on 
MPM cell proliferation, cell cycle, apoptosis induction, 
and invasive behavior on a panel of cell lines, in order 
Figure 7: A. Role of PDGFRB in apoptosis, following treatment with crenolanib. Caspase activity measured on Mero-14, IstMes2, Mero-
25, and Met5A cells treated with DMSO (set to 1, dotted black bar), or crenolanib (1µM). A marked increase in apoptosis is observed for 
Mero-14 and IstMes2 cells. A slight induction of apoptosis is also reach by Mero-25 and Met5A cells, after treatment with crenolanib. Error 
bars represent SEM of three independent experiments, each performed in triplicate. B. Role of PDGFRB in cellular migration, following 
treatment with crenolanib, and imatinib. Confluent monolayers of Mero-14, IstMes2, and Mero-25 cells treated with 1µM of crenolanib 
(top), or 25µM of imatinib (bottom). Massive effect was observed in the wound-healing assay, following crenolanib treatment for Mero-14, 
IstMes2, and Mero-25 cells. Imatinib treatment impaired the migration ability of Mero-14 and Mero-25 cells, but not of IstMes2 cells. Two 
independent experiments were carried out, each performed in triplicate.
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to widen the cancer representativeness. The transient 
PDGFRB-silencing caused a decrease in the proliferation 
rate and a reduced colony formation capacity of Mero-
14 and IstMes2 cell lines, as well as in anchorage-
independent growth conditions. Moreover, PDGFRB 
depletion was associated with an increase in the share 
of cells in sub-G1 phase, as well as with an increased 
apoptotic rate of these cells. These data are in agreement 
with those observed by McGary, who demonstrated that 
the selective inhibition of the PDGFR tyrosine kinase 
through STI571 slowed PDGF-mediated growth and led 
to apoptosis of osteosarcoma cells in vitro [8]. In addition, 
Wang and co-workers showed that PDGFRB inhibition 
alone reduces spontaneous growth and metastasis in 
Ewing Sarcoma (EWS) [21]. In further work they 
demonstrated that PDGFRB depletion is fundamental in 
increasing the activity of TRAIL (tumor necrosis factor-
related apoptosis-inducing ligand) for the significant 
reduction of growth of EWS, as well as decreasing the 
number of incidences of spontaneous EWS pulmonary 
metastasis [22]. In a previous work, Zhang and co-workers 
showed that altered phosphorylation at the tyrosine kinase 
domain may potentially induce impaired signaling via 
the PDGF-B/PDGFRβ pathway, triggering a series of 
intracellular kinase cascades, such as those of Ras/Raf, 
MAPK, PI3K/AKT and FAK [23]. Their activation would 
then act as a proliferative stimuli and lead to the inhibition 
of apoptosis [24-26].
IstMes2 and Mero-14 cells underwent an 
accumulation in G2/M phase after siPDGFRB treatment. 
Figure 8: Role of PDGFRB in anchorage-independent growth capacity following drugs inhibitors treatments. 
Representative images of soft agar colonies formed by DMSO, crenolanib and imatinib treated Mero-14, IstMes2 and Met5A cell lines 
(top) and the corresponding histograms of each measurement (bottom). Error bars represent SEM of two independent experiments, each 
performed in triplicate.
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This data suggests that inhibition of PDGFRB could 
determine the G2 checkpoint recovery arrest. Indeed, 
a role of PDGFRB in the G2 checkpoint was suggested 
in work by Sun and co-workers [27]. More recently, 
in support of this hypothesis, it has been shown that 
imatinib delayed recovery from checkpoint arrest and 
inhibited the subsequent S-G2-M transition, through a 
persistent activation of ATR-Chk1 signaling, known to 
be fundamental for the maintenance of G2 checkpoint 
arrest. For this reason, the authors suggested that imatinib 
may inhibit resumption of tumor proliferation after 
chemotherapy [28]. 
Loss of migration ability in the IstMes2 cell 
line, following PDGFRB siRNA administration, was 
also observed. This data is in agreement with studies 
highlighting how PDGFRB activity is involved not only 
in cell growth, but also in the MPM chemotaxis. To 
support these results, experiments using UTI, a urinary 
trypsin inhibitor that neutralizes the activation of PDGFRβ 
cascade, showed that migration of MPM cells is inhibited 
[29]. Moreover, Abouantoun and co-workers showed 
PDGFRB tyrosine kinase activity is critical for migration 
and invasion of medulloblastoma cells, possibly by trans-
activating EGFR, and thus its depletion may represent an 
important therapeutic strategy for the treatment of this 
cancer [30].
Therefore, our results have shown that reverting 
PDGFRB over-expression can affect cell growth, 
migration and apoptosis in MPM cell lines. Interestingly, 
non-malignant cells (Met5A) did not seem to be affected 
by the PDGFRB silencing, suggesting that this gene might 
be an effective therapeutic target. These evidences together 
with the fact that a plethora of PDGFRB inhibitors are 
currently employed in a series of clinical trials, prompted 
us to investigate whether the phenotypic effect obtained 
with transient transfection of MPM cell lines could be 
confirmed through the use of drug inhibitors such as 
crenolanib or imatinib.
The similar results observed between crenolanib and 
siPDGFRB confirmed that the effects induced by this drug 
could be largely mediated through PDGFRB inactivation 
(being crenolanib designed to be a specific PDGFR 
inhibitor). Interestingly, both crenolanib and imatinib 
were effective on Mero-25 cells, that did not respond 
well to gene silencing, likely due to the weak transfection 
efficiency found with this cell line. Alternatively, 
crenolanib and imatinib could inhibit other tyrosine kinase 
receptors activities inducing increased effects on -Mero-
25 cells. In fact, we are aware that the specificity of these 
inhibitors on PDGFRB is reduced as compared to that of 
gene silencing. This may explain the variable responses 
observed among the different MPM cell lines, also in 
relation to the different endogenous levels of PDGFRA 
and FLT3 expressed by Mero-14, IstMes2, and Mero-25 
cells (Supplementary Figure 1). Indeed, crenolanib is a 
potent and selective inhibitor also of PDGFRA and FLT3 
(the FMS-related tyrosine kinase 3), whereas imatinib is a 
tyrosine kinase inhibitor (TKI) targeting also BCR-ABL, 
KIT, and PDGFRA. 
As regard imatinib, Bertino and co-workers [2], have 
reported that this drug has the ability to induce cytotoxicity 
and apoptosis selectively on PDGFRB positive MPM cells 
via blockade of receptor phosphorylation and interference 
with the Akt pathway. To our knowledge, crenolanib has 
never been tested in MPM. We compared the effect of both 
the inhibitors, clearly establishing the major efficacy of 
crenolanib on blocking the malignant phenotype of MPM 
cells. Indeed, crenolanib has been shown as more efficient 
than imatinb, even at lower doses, with a Ki about 30 
times less than imatinib. Crenolanib is a potent class III 
receptor tyrosine kinase inhibitor including PDGFRB, 
with minimal toxicity, whose therapeutic efficacy has 
already been validated through clinical trials in GIST and 
human acute myeloid leukemia. Moreover, preclinical 
evidences showed benefit for lung cancer patients with 
deregulated PDGFR signaling [31].
Thus, our findings provided a rationale to explore 
further the efficacy of crenolanib in MPM patients, when 
characterized by an over-expression of PDGFRB, with 
promising results greater than those obtained with the 
use of imatinib. Indeed, previous clinical trials suggested 
that imatinib, as a single agent, has a limited efficacy in 
MPM patients [32,33]. The introduction of crenolanib 
may represent a robust strategy to improve the survival 
of MPM patients who present with PDGFRB positivity. 
In conclusion, this study highlights the importance 
of the role played by PDGFRB in the MPM malignancy 
and has provided a rationale for its use as a potential 
therapeutic target. We also suggest that crenolanib could 
be an important therapeutic option for MPM patients, 
which warrants further investigation in order to explore 
its usefulness as a form of personalized therapy for this 
cancer type.  
MATERIALS AND METHODS
Tissue collection and DNA sequencing
Ninety-six samples from formalin fixed and paraffin 
embedded tissues (FFPE) of MPM patients hospitalized 
and surgically resected for the tumor were enrolled for 
PDGFRB mutation screening. According to the Helsinki 
declaration, the local ethical committee approved the 
study. All tumor samples used in this study were selected 
and dissected by an experienced pathologist. Demographic 
information is reported in Table S3. FFPE sections were 
de-paraffined by submersion in xylene; the tissue was then 
incubated overnight at 56°C with Proteinase K (Qiagen, 
UK) to allow samples lysis and DNA was extracted using 
the Trizol reagent (Invitrogen, CA, USA) following the 
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manufacturer’s instructions. To obtain RNA free genomic 
DNA, an RNase A (Qiagen, UK) treatment was performed 
following the protocol instructions. The concentration 
and purity of the isolated DNA were measured using 
a NanoDrop ND-1000 Spectrophotometer (Thermo 
Fisher Scientific, DE, USA). Subsequently, the mutation 
screening was performed with automatic sequencing 
(Sanger reaction), according to the standard protocol. 
Specifically, the whole exons 12 and 18 of PDGFRB 
were PCR-amplified from genomic DNA using the 
specific primer pairs: Forward= tgtcctagacggacgaacct 
(Exon 12) and gaagggtctttccccacaat (Exon 18) Reverse= 
ccaacttgagtccccacact (Exon 12), and cacactggtcaggagggaat 
(Exon 18) and sequenced using PCR oligonucleotide as 
sequencing primer.
Copy number alterations data of 83 MPM patients 
were obtained from Cancer Genome Atlas (TCGA) 
consortium.
Cell cultures
The mesothelial non-MPM immortalized cell 
line (Met5A), was purchased from ATCC and grown in 
Medium 199 with HEPES (Life Technologies, Monza, 
Italy) supplemented with 10% FCS, 3.3 nM epidermal 
growth factor (EGF, Life Technologies, Monza, Italy), 400 
nM hydrocortisone (Sigma Aldrich Corp. St Louis, MO, 
USA), and 870 nM insulin (Life Technologies, Monza, 
Italy). Three mesothelioma cell lines (Mero-14, Mero-
25, and IstMes2), kindly donated by Istituto Tumori of 
Genova (Italy), were cultured in DMEM medium (Lonza, 
Basel, Switzerland), with 10% of FCS. 
PDGFRB inhibitors and PDGFRB silencing RNA 
oligonucleotide 
Imatinib (Cayman Chemical, Michigan, USA) 
and Crenolanib (Selleckman) were dissolved in DMSO 
to give a final concentration of 10 mM, and used at the 
previously established IC30 concentration, that is of 25 µM 
and 1 µM respectively. The following primary antibodies 
were used: primary mouse monoclonal anti-PDGFRB, 
anti-PDGFRA, and anti-FLT3 (Santa Cruz, TX, USA; 
1:300) or mouse monoclonal anti-ß-actin (Anti-Actin, 
Clone C4, Millipore, MA, USA; 1:5000). IgG-HRP Santa 
Cruz (1:5000) was used as secondary antibody. Different 
silencing-RNAs (siRNAs) were tested, and purchased 
from Qiagen (Qiagen, UK). Further experiments were 
performed by using a single specific siRNA for PDGFRB 
(SI00605738, the so-called “siPDGFRB” now-on) and the 
‘‘AllStars Negative Control siRNA’’ (SI03650318, used as 
non-targeting control - the so-called “C- PDGFRB” now-
on). siRNA oligonucleotides were re-suspended in the 
provided buffer at a final stock concentration of 20 mM, 
and employed at 50nM in each experiments. HiPerfect 
transfection reagent was employed for siRNA trasfection 
(Qiagen, UK), as previously described [16]. 
RNA isolation, Quantitative Real-Time PCR (RT-
qPCR) and Western Blotting
These three techniques were performed as 
previously described [16,34]. Densitometry results of 
western blot were analysed with Image J software (NIH, 
Bethesda, MD, USA). For quantitative analysis, the 
signal intensity of each band was normalized with ß-actin 
densitometry values. Each density was compared to the 
intensity of the reference cell line (Met5A) and all western 
blot analyses were replicated twice for the calculation of 
the average increase.
Sulphorhodamine (SRB) assay
Cells were seeded in 96-well plates at a density of 3 
X 103. The next day, (day 0), one plate was assessed. The 
remaining plates were tested at 2-day intervals for a total 
of 8 days. Cells were fixed with 100 μL per well of ice-
cold 40% (vol/vol) TCA (Sigma Aldrich Corp. St Louis, 
MO, USA), and then stained with 0.4% SRB solution 
(Sigma Aldrich Corp. St Louis, MO, USA). After staining, 
unbound dye was removed by washing five times with 1% 
acetic acid solution and left to air dry. The bound SRB 
dye was then solubilized by adding unbuffered Tris-base 
solution, and plates were then read at OD 492 nm, using a 
microplate reader.
Determination of drugs’ doses
Sub-confluent cells in 96-well plates were exposed 
for 48 h to medium supplemented with 2% FBS, with or 
without crenolanib (in a range of concentrations from 20 
µM to 0.3 µM) or imatinib (in the range from 200 µM 
to 0.1 µM). The different concentration ranges have 
been chosen based on previous literature searches. Cell 
viability was assessed by SRB assay on 3 replicates at 
each concentration point to determine single drug lethal 
concentration values and their critical IC50 and IC30 values. 
Normalised cytotoxicity percentages were obtained from 
the formula: (A570 mean values of extracts from treated 
samples/A570 mean values of extracts from untreated 
control samples) X 100. Because the dose-response 
relationship was similar in all employed cell lines (data not 
shown for brevity), the unique dose of 1µM for crenolanib 
and 25µM for imatinib (corresponding to the IC30 for both 
of them) was used for all the assays.
Genes & Cancer450www.impactjournals.com/Genes&Cancer
Colony formation assays
3X103 cells were seeded in a 96-well plate and, 
after 24 h, transfected with the correct concentration of 
siPDGFRB, or treated with PDGFRB inhibitors. After 24 
h post treatment, cells were transferred in 6-well plates 
and incubated for a further 14 days. Following 14 days 
incubation, growth medium was removed and cells fixed 
and stained in 10% ethanol solution containing 0.1% 
crystal violet for 1 h. Colonies were then counted and 
measured with Image J software.
Flow cytometry (FACS)
After siRNA transfection or drug treatments for 
72 h, 105 cells were collected, washed in phosphate-
buffered saline (PBS), pelleted by centrifugation and 
fixed in 70% ethanol. Immediately prior to staining, cells 
were suspended in PBS containing 50 μg/ml of RNAse 
A (Qiagen, UK), and then, stained with propidium iodide 
(final concentration 100 µg/ml) overnight at 4°C. The 
percentage of cells in subG1, G0/G1, S and G2/M phases 
were determined from 10.000 cells using the BD C6 
ACCURI Software (Becton Dickinson). The experiments 
were carried out three independent times (triplicates).
Caspase - GloH 3/7 assay
Caspase-3/7 activation was measured using the 
Caspase-Glo 3/7 Luminescence Assay (Promega Corp. 
Madison, Wisc., USA) according to the manufacturer’s 
instructions. In a 6-well plate 3X105 cells were incubated. 
The day after, the cells were treated with siRNAs or 
PDGFRB inhibitors, for 72 h. Then, the cells were 
collected by trypsinization, and approximately 15X103 
cells were transferred in a 96-well white plate. Caspase-
3/7-Glo reagent was added, and the samples were 
incubated at 37°C for 1 h. The luminescence that is 
proportional to the caspase 3/7 activities was determined 
by luminometer (Tecan Sunrise, Austria GMBH).
Wound-Healing Assay
25X103 cells were seeded in a 6-well plate and, 
after 24h, transfected with siRNAs or PDGFRB inhibitors 
for 72 h. A linear scratch in the confluent cell monolayer 
was made with a sterile pipette tip after 39 h (time 
optimized following preliminary trials) following siRNA 
transfection. Then, cells were rinsed and incubated in full 
medium. Finally, cells were photographed at 72 h (i.e. 33h 
following the scratch) with an optical microscope at 10X 
magnification connected to a computer. The migration was 
then evaluated on the images, and measured using Image 
J software.
Soft agar assay for colony formation 
Base layer of soft agar was prepared by pouring 
1 mL of 0.9% agar in MPM cells media in each well of 
6-well plates and allowed to polymerize for few minutes. 
Top layer of soft agar was prepared using 0.45% agar in 
MPM cells media and cells from each treatment groups 
(C-PDGFRB vs siPDGFRB; DMSO vs crenolanib and 
imatinib) were mixed (10.000 cells in 1 mL soft agar 
solution) and plated over the base layer in each well. 
All the soft agar plates were allowed to solidify and 
then maintained at 37°C with a humidified atmosphere 
containing 5% CO2. Colony formation of cells on soft 
agar was monitored by microscopic observation on daily 
basis. On Day 14, colonies were counted manually using 
microscope and representative images were taken. 
Statistical analyses
The measurements of gene expression performed on 
cell lines, and the results obtained from the in vitro assays 
were statistically evaluated using a two-tailed Student’s 
t-test. The effects of the combination of treatments (drugs 
+/– siRNAs) were evaluated with a multifactor analysis 
of variance (MANOVA) model. The statistics were 
performed with the software Statgraphics Centurion XV 
(StatPoint, Inc.).
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